Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor

Cancer Research

Volumn 62, Issue 1, 2002, Pages 165-170

  Rao, Chinthalapally V ^a   Indranie, Cooma ^a   Simi, Barbara ^a   Reddy, Bandaru S ^a   Manning, Pamela T ^b   Connor, Jane R ^b  

^a AMERICAN HEALTH FOUNDATION   (United States)

^b Arthritis and Inflammation Pharmacology Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; AZOXYMETHANE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ENZYME INDUCING AGENT; N6 (1 IMINOETHYL)LYSINE TETRAZOLE AMIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SC 51; SULINDAC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; CRYPT CELL; DIET; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT;

ANIMALS; ANTICARCINOGENIC AGENTS; AZOXYMETHANE; BODY WEIGHT; CARCINOGENS; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG SYNERGISM; ENZYME INHIBITORS; HOMOARGININE; INTESTINAL MUCOSA; ISOENZYMES; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, INBRED F344; SULFONAMIDES;

EID: 0036144387     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Cancer statistics
2. Risk factors for colon neoplasia. Epidemiology and biology
3. Colon cancer: A role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs
4. Aspirin and potential role of prostaglandins in colon cancer
5. Prostanoid biosynthesis and mechanisms of action
6. Biological effects of nonsteroidal anti-inflammatory drugs
7. Cyclooxygenase-2 inhibitors in tumorigenesis (part I)
8. Cyclooxygenase in biologydisease
9. Evaluation of cyclooxygenase-2 inhibitor for the potential chemopreventive properties in colon carcinogenesis
10. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
11. Chemoprevention of colonic aberrant crypt foci by cyclooxygenase inhibitors
12. Δ716 knockout mice by inhibition of cyclooxygenase 2
13. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
14. Celecoxib: A new option in the treatment of arthropathies and familial adenomatous polyposis
15. Cyclooxygenase-2 inhibitors in tumorigenesis (part 11)
16. Nitric oxide: Physiology, pathophysiology, and pharmacology
17. Nitric oxide synthases: Roles, tolls, and controls
18. Nitric oxide synthase: Expression and expressional control of the three isoforms
19. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor
20. Nitric oxide synthase activity in human gynecological cancer
21. Nitric oxide synthase activity in human breast cancer
22. Expression of nitric oxide synthase in human central nervous system tumors
23. Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis
24. Frequent nitric oxide synthase-2 expression in human colon adenomas: Implication for tumor angiogenesis and colon cancer progression
25. Chemoprevention of colon cancer by iNOS specific and non-specific inhibitors: A safer colon cancer chemopreventive strategy
26. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane
27. DNA damage by nitric oxide
28. Inflammatory cytokines induce DNA damage and inhibit DNA repair in colonic carcinoma cells by a nitric oxide dependent mechanism
29. Nitric oxide nitrates tyrosine residues of tumor suppressor p53 protein in MCF-7 cells
30. Role of angiogenesis and microcirculation in tumors
31. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis
32. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: Putative preneoplastic lesions
33. Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions
34. Molecular determinants of dysplasia in colorectal lesions
35. Chemoprevention of colon carcinogenesis by phenylethyl-3-methylcaffeate
36. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon
37. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug and with D, L-α-difluoromethylornithine, an omithine decarboxylase inhibitor, in the diet
38. Roles of nitric oxide in tumor growth
39. Regulation of prostaglandin production by nitric oxide: An in vivo analysis
40. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
41. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages
42. Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase 2
43. Chemoprevention of colon cancer by the specific cyclooxygenase-2 inhibitor, celecoxib, administered during the different stages of carcinogenesis
44. Arachidonic acid oxygenation by COX-1 and COX-2
45. AG is an isoform-selective, mechanism-based inactivator of nitric oxide synthase
46. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms
47. Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism
48. The influence of catabolic reactions on polyamine excretion
49. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
50. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors
51. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, difluoromethylomithine, 16-α-fluoro-5-androsten-17-one and ellagic acid individually and in combination
52. Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis